“…It remains to be seen whether the positive effect of lamivudine will be durable or whether maintenance lamivudine therapy will be required. Dosages of 100 mg of lamivudine per day have resulted in sustained HBeAg seroconversion rates of 27% and histologic improvement rates of up to 50% after 2 years of therapy in immunocompetent patients, but mutations in the YMDD motif of the viral polymerase gene, leading to antiviral resistance, develop in up to one third of patients [25]. These mutations do not seem to confer cross-resistance to other antiviral agents [26].…”